Urology
Volume 71, Issue 1 , Pages 151-155 , January 2008

The Effect of Race/Ethnicity on the Accuracy of the 2001 Partin Tables for Predicting Pathologic Stage of Localized Prostate Cancer

  • Elisabeth I. Heath

      Affiliations

    • Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
    • Corresponding Author InformationReprint requests: Elisabeth I. Heath, M.D., Karmanos Cancer Institute, Department of Hematology and Oncology, Wayne State University, 4100 John R, 4 HWCRC, Detroit, MI 48201.
    • ,
  • Michael W. Kattan

      Affiliations

    • Cleveland Clinic, Cleveland, Ohio
    • ,
  • Isaac J. Powell

      Affiliations

    • Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
    • ,
  • Wael Sakr

      Affiliations

    • Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
    • ,
  • Timothy C. Brand

      Affiliations

    • The University of Texas Health Science Center at San Antonio, San Antonio, Texas
    • ,
  • Benjamin A. Rybicki

      Affiliations

    • Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
    • Department of Biostatistics and Research Epidemiology, Henry Ford Health System, Detroit, Michigan
    • ,
  • Ian M. Thompson

      Affiliations

    • The University of Texas Health Science Center at San Antonio, San Antonio, Texas
    • ,
  • William J. Aronson

      Affiliations

    • Greater Los Angeles Department of Veterans Affairs (VA) and University of California, Los Angeles, Los Angeles, California
    • ,
  • Martha K. Terris

      Affiliations

    • Augusta VA and Medical College of Georgia, Augusta, Georgia
    • ,
  • Christopher J. Kane

      Affiliations

    • San Francisco VA and University of California, San Francisco, San Francisco, California
    • ,
  • Joseph C. Presti Jr.

      Affiliations

    • Stanford University and Palo Alto VA, Palo Alto, California
    • ,
  • Christopher L. Amling

      Affiliations

    • University of Alabama Birmingham and Birmingham VA, Birmingham, Alabama
    • ,
  • Stephen J. Freedland

      Affiliations

    • Durham VA and Duke University, Durham, North Carolina

Received 19 April 2007 ,Accepted 10 August 2007.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  2. Stanford JL, Stephenson RA, Coyle LM, et al. Prostate Cancer Trends 1973–1995: SEER Program, National Cancer Institute. NIH Pub. No. 99-4543. Bethesda, Maryland: National Institutes of Health; 1999;
  3. Gilligan T, Wang PS, Levin R, et al. Racial differences in screening for prostate cancer in the elderly. Arch Intern Med. 2004;164:1858–1864
  4. Freedland SJ, Isaacs WB. Explaining racial differences in prostate cancer in the United States: sociology or biology?. Prostate. 2005;62:243–252
  5. Mohler JL, Gaston KE, Moore DT, et al. Racial differences in prostate androgen levels in men with clinically localized prostate cancer. J Urol. 2004;171:2277–2280
  6. Shuch B, Mikhail M, Satagopan J, et al. Racial disparity of epidermal growth factor receptor expression in prostate cancer. J Clin Oncol. 2004;22:4725–4729
  7. Stephenson AJ, Kattan MW. Nomograms for prostate cancer. BJU Int. 2006;98:39–46
  8. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer (A multi-institutional update). JAMA. 1997;277:1445–1451
  9. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001;58:843–848
  10. Freedland SJ, Amling CL, Dorey F, et al. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology. 2002;60:670–674
  11. Bianco FJ, Kattan MW, Scardino PT, et al. Radical prostatectomy nomograms in black American men: accuracy and applicability. J Urol. 2003;170:73–76discussion 76–77
  12. Rybicki BA, Neslund-Dudas C, Nock NL, et al. Prostate cancer risk from occupational exposure to polycyclic aromatic hydrocarbons interacting with the GSTP1 Ile105Val polymorphism. Cancer Detect Prev. 2006;30:412–422
  13. Thompson KE, Hernandez J, Canby-Hagino ED, et al. Prognostic features in men who died of prostate cancer. J Urol. 2005;174:553–556discussion 556
  14. Blute ML, Bergstralh EJ, Partin AW, et al. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol. 2000;164:1591–1595
  15. Aleman M, Karakiewicz PI, Kupelian P, et al. Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening. Urology. 2003;62:70–74
  16. Eskicorapci SY, Karabulut E, Turkeri L, et al. Validation of 2001 Partin tables in Turkey: a multicenter study. Eur Urol. 2005;47:185–189
  17. Garzotto M, Wajsman Z. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup. J Urol. 1998;159:950–954discussion 954–955
  18. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006;98:715–717
  19. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433–439
  20. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110–114
  21. Cross CK, Shultz D, Malkowicz SB, et al. Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate. J Clin Oncol. 2002;20:2863–2868
  22. Nielsen ME, Han M, Mangold L, et al. Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center. J Urol. 2006;176:515–519
  23. Bastian PJ, Gonzalgo ML, Aronson WJ, et al. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer. 2006;107:1265–1272
  24. D’Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125–135
  25. D’Amico AV, Whittington R, Malkowicz SB, et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol. 2000;18:1164–1172
  26. Freedland SJ, Terris MK, Csathy GS, et al. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. J Urol. 2004;171:2215–2220
  27. Freedland SJ, Isaacs WB, Platz EA, et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol. 2005;23:7546–7554
  28. Freedland SJ, Aronson WJ, Kane CJ, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol. 2004;22:446–453
  29. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2005;23:7005–7012

 Supported by the Fund for Cancer Research, the Karmanos Cancer Institute (Detroit, Michigan), the U.S. Department of Defense, the U.S. Department of Veterans Affairs, the Georgia Cancer Coalition, the National Institutes of Health, and the American Urological Association Astellas Rising Star in Urology Award.

PII: S0090-4295(07)01998-X

doi: 10.1016/j.urology.2007.08.016

Urology
Volume 71, Issue 1 , Pages 151-155 , January 2008

Article Tools

* Image Usage & Resolution